Jefferies Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.86M | Sell |
47,911
-4,998
| -9% | -$200K | 0.02% | 635 |
|
|
2022
Q2 | $1.97M | Sell |
52,909
-615
| -1% | -$25K | 0.02% | 617 |
|
|
2022
Q1 | $2.37M | Buy |
53,524
+19,009
| +55% | +$824K | 0.01% | 628 |
|
|
2021
Q4 | $1.47M | Sell |
34,515
-22,119
| -39% | -$929K | 0.01% | 889 |
|
|
2021
Q3 | $2.46M | Sell |
56,634
-33,666
| -37% | -$1.49M | 0.02% | 690 |
|
|
2021
Q2 | $3.86M | Buy |
90,300
+1,386
| +2% | +$58.3K | 0.02% | 542 |
|
|
2021
Q1 | $3.44M | Buy |
88,914
+68,909
| +344% | +$2.61M | 0.03% | 502 |
|
|
2020
Q4 | $719K | Sell |
20,005
-144,351
| -88% | -$5.2M | 0.01% | 1030 |
|
|
2020
Q3 | $6.28M | Buy |
164,356
+134,990
| +460% | +$5.2M | 0.07% | 237 |
|
|
2020
Q2 | $1.03K | Buy |
29,366
+81
| +0.3% | +$2.92K | 0.01% | 743 |
|
|
2020
Q1 | $956K | Sell |
29,285
-58,100
| -66% | -$2.27M | 0.01% | 1026 |
|
|
2019
Q4 | $3.95M | Buy |
87,385
+50,454
| +137% | +$2.11M | 0.03% | 638 |
|
|
2019
Q3 | $1.5M | Sell |
36,931
-15,409
| -29% | -$653K | 0.01% | 1256 |
|
|
2019
Q2 | $2.25M | Sell |
52,340
-41,010
| -44% | -$1.58M | 0.02% | 863 |
|
|
2019
Q1 | $3.58M | Buy |
93,350
+46,213
| +98% | +$1.77M | 0.03% | 582 |
|
|
2018
Q4 | $1.67M | Buy |
47,137
+13,936
| +42% | +$505K | 0.01% | 909 |
|
|
2018
Q3 | $1.28M | Sell |
33,201
-32,677
| -50% | -$1.14M | 0.01% | 1208 |
|
|
2018
Q2 | $2.15M | Buy |
65,878
+57,525
| +689% | +$1.73M | 0.01% | 852 |
|
|
2018
Q1 | $228K | Sell |
8,353
-257,334
| -97% | -$6.99M | ﹤0.01% | 1917 |
|
|
2017
Q4 | $6.59M | Buy |
265,687
+259,287
| +4,051% | +$7.15M | 0.03% | 462 |
|
|
2017
Q3 | $187K | Sell |
6,400
-42,228
| -87% | -$1.17M | ﹤0.01% | 2086 |
|
|
2017
Q2 | $1.35M | Sell |
48,628
-213,934
| -81% | -$5.68M | 0.01% | 1144 |
|
|
2017
Q1 | $6.53M | Buy |
262,562
+210,288
| +402% | +$5.11M | 0.05% | 400 |
|
|
2016
Q4 | $1.13M | Sell |
52,274
-62,872
| -55% | -$1.37M | 0.01% | 1205 |
|
|
2016
Q3 | $2.74M | Buy |
115,146
+73,661
| +178% | +$1.76M | 0.01% | 787 |
|
|
2016
Q2 | $970K | Buy |
+41,485
| New | +$897K | ﹤0.01% | 1161 |
|
|
2016
Q1 | – | Sell |
-41,504
| Closed | -$765K | – | 2218 |
|
|
2015
Q4 | $765K | Buy |
41,504
+3,882
| +10% | +$69.6K | ﹤0.01% | 1302 |
|
|
2015
Q3 | $617K | Buy |
37,622
+37,022
| +6,170% | +$633K | ﹤0.01% | 1419 |
|
|
2015
Q2 | $11K | Sell |
600
-49,897
| -99% | -$892K | ﹤0.01% | 2773 |
|
|
2015
Q1 | $896K | Buy |
+50,497
| New | +$798K | 0.01% | 1104 |
|
|
2014
Q4 | – | Sell |
-142,368
| Closed | -$1.68M | – | 1964 |
|
|
2014
Q3 | $1.68M | Buy |
142,368
+128,195
| +905% | +$1.61M | 0.01% | 794 |
|
|
2014
Q2 | $181K | Sell |
14,173
-28,191
| -67% | -$367K | ﹤0.01% | 1789 |
|
|
2014
Q1 | $573K | Sell |
42,364
-11,201
| -21% | -$147K | 0.01% | 1196 |
|
|
2013
Q4 | $644K | Sell |
53,565
-109,841
| -67% | -$1.3M | ﹤0.01% | 1027 |
|
|
2013
Q3 | $1.92M | Buy |
163,406
+132,760
| +433% | +$1.44M | 0.02% | 621 |
|
|
2013
Q2 | $284K | Buy |
+30,646
| New | +$260K | ﹤0.01% | 1346 |
|
Other funds holding BSX
BG
Jefferies Group's BSX Position: Q3 2022 in Review
Jefferies Group reduced its Boston Scientific (BSX) stake by 9.4% in Q3 2022, selling an estimated $200K and leaving 47,911 shares worth $1.86M. The position accounts for 0.02% of the portfolio, ranked #635.
Jefferies Group first reported a position in BSX in Q2 2013 and has held it in 36 quarters since. The position peaked at $6.59M in Q4 2017. 864 funds tracked by Wall St. Rank hold BSX as of Q3 2022.
- Jefferies Group held 47,911 shares of Boston Scientific worth $1.86M as of Q3 2022.
- Jefferies Group sold 4,998 Boston Scientific shares in Q3 2022, an estimated $200K.
- Boston Scientific made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #635 holding.
- Jefferies Group first reported a position in Boston Scientific in Q2 2013 and has held it in 36 quarters since.
- Jefferies Group's Boston Scientific position peaked at $6.59M in Q4 2017.
- 864 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.